Search NLS News

Ultimovacs has announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for the company’s US application for a patent covering methods for eliciting a T cell immune response with the UV1 universal cancer vaccine. Subject to grant formalities, the company expects that the patent will issue with a […]

Elekta has received CE mark for its Elekta Esprit, a new Leksell Gamma Knife radiosurgery platform. This regulatory clearance is the first step in enabling people with brain disease in Europe and other countries where the CE mark is recognized – and successively the rest of the world – to receive treatment with this state-of-the […]

iZafe Group has signed a letter of intent with Pilloxa regarding the acquisition of 100 per cent of the shares in Pilloxa. Pilloxa has developed a technology platform for better compliance that pharmaceutical companies use to design digital patient support. The acquisition creates a new company in digital health that is well positioned to become […]

The company’s TetraGraph-system has now received FDA 510k-clearance for use in children with the disposable sensor TetraSens Pediatric. Senzime can thus broaden the indication for TetraGraph to also monitor infants and young children who have received muscle paralyzing drugs as part of anesthesia, the company states. Currently sold in 29 countries Senzime’s system for monitoring […]

The Board has initiated this review aiming to optimize shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin and implement a restructuring of the company. The company’s Board of Directors has appointed Carnegie Investment Bank to explore strategic options available to the company. “The decision to discontinue […]

Oncopeptides has announced that the European Commission has granted Pepaxti marketing authorization in combination with dexamethasone. The approval concerns the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, […]

Ultimovacs has completed treatment of three patients at the highest dose cohort in the phase I TENDU trial without any safety concerns. Based on these results, the company plans to enroll up to three additional patients at the highest dose level, it states. “We are very encouraged by the continuing progress of the phase I […]

The two companies have announced an expansion of their collaboration to develop and commercialize novel immunotherapies for the treatment of cancer patients. Under the expansion, Genmab and BioNTech will jointly work to research, develop, and commercialize novel monospecific antibody candidates for various cancer indications. Since 2015, the companies have been working on the joint development […]

Idogen has announced that an Extraordinary General Shareholder Meeting will be convened to propose the election of two new members to the Board of Directors: Joakim Söderström and Niklas Wallett, representing a consortium that owns approximately 17% of the votes. The election of Joakim Söderström as new Chairman of the Board has also been proposed. […]

Private equity fund EQT has made a cash offer for the remaining shares in Swedish biopharmaceuticals group Karo Pharma. EQT currently owns 86% of Karo Pharma. The total value of the offer is 2.23 billion Swedish crowns ($215.15 million), valuing Karo Pharma at 16.4 billion, EQT subsidiary Karo Intressenter said in a statement. In 2018, […]